NO20025290L - Fremgangsmåter og blandinger for behandling og forhindring av glattmuskelcelle-proliferasjon - Google Patents

Fremgangsmåter og blandinger for behandling og forhindring av glattmuskelcelle-proliferasjon

Info

Publication number
NO20025290L
NO20025290L NO20025290A NO20025290A NO20025290L NO 20025290 L NO20025290 L NO 20025290L NO 20025290 A NO20025290 A NO 20025290A NO 20025290 A NO20025290 A NO 20025290A NO 20025290 L NO20025290 L NO 20025290L
Authority
NO
Norway
Prior art keywords
compositions
treating
methods
cell proliferation
smooth muscle
Prior art date
Application number
NO20025290A
Other languages
English (en)
Other versions
NO20025290D0 (no
Inventor
Sivaram Pillarisetti
Original Assignee
Sivaram Pillarisetti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sivaram Pillarisetti filed Critical Sivaram Pillarisetti
Publication of NO20025290D0 publication Critical patent/NO20025290D0/no
Publication of NO20025290L publication Critical patent/NO20025290L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20025290A 2001-03-02 2002-11-04 Fremgangsmåter og blandinger for behandling og forhindring av glattmuskelcelle-proliferasjon NO20025290L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27295101P 2001-03-02 2001-03-02
PCT/US2002/006471 WO2002069899A2 (en) 2001-03-02 2002-03-04 Methods and compositions for the treatment and prevention of smooth muscle cell proliferation

Publications (2)

Publication Number Publication Date
NO20025290D0 NO20025290D0 (no) 2002-11-04
NO20025290L true NO20025290L (no) 2002-11-18

Family

ID=23041926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025290A NO20025290L (no) 2001-03-02 2002-11-04 Fremgangsmåter og blandinger for behandling og forhindring av glattmuskelcelle-proliferasjon

Country Status (9)

Country Link
US (1) US20020182587A1 (no)
EP (1) EP1410034A4 (no)
AU (1) AU2002335493A1 (no)
DK (1) DK200201681A (no)
FI (1) FI20021948A (no)
IL (1) IL152611A0 (no)
NO (1) NO20025290L (no)
SE (1) SE0203237L (no)
WO (1) WO2002069899A2 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141598A1 (en) * 1992-08-12 1994-03-03 Tikva Vogel Method of inhibiting cell proliferation using apolipoprotein e
US6306613B1 (en) * 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
WO2001037853A2 (en) * 1999-11-23 2001-05-31 North Shore - Long Island Jewish Health System Methods and agents for the inhibition of smooth muscle cell proliferation

Also Published As

Publication number Publication date
SE0203237L (sv) 2002-12-13
SE0203237D0 (sv) 2002-11-04
EP1410034A2 (en) 2004-04-21
NO20025290D0 (no) 2002-11-04
US20020182587A1 (en) 2002-12-05
AU2002335493A1 (en) 2002-09-19
WO2002069899A2 (en) 2002-09-12
IL152611A0 (en) 2003-06-24
FI20021948A (fi) 2002-12-31
WO2002069899A3 (en) 2002-12-19
DK200201681A (da) 2002-12-20
EP1410034A4 (en) 2005-03-16
FI20021948A0 (fi) 2002-11-01

Similar Documents

Publication Publication Date Title
EP1545578A4 (en) COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
AU2003243373A8 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
GB0110288D0 (en) Composition and treatment method
NO20005017D0 (no) Metoder og viskøse sammensetninger for behandling av brønner
EP1468118A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP1572118A4 (en) METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
EP1512415A4 (en) LURE COMPOSITION FOR TREATING AND PREVENTING INFLAMMATORY DISEASES
AU2003212850A8 (en) Methods and compositions for treating cardiovascular disease
AU2002367023A8 (en) Compositions and methods for treating heart failure
AU2003297573A8 (en) Compositions and methods for treating transplants
GB0303609D0 (en) Novel therapeutic method and compositions
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
AU2002365057A8 (en) Compositions and methods for treating heart failure
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
DK1441746T3 (da) Sammens tning og fremgangsmode
NO20025290L (no) Fremgangsmåter og blandinger for behandling og forhindring av glattmuskelcelle-proliferasjon
AU2003275433A8 (en) Compositions and methods for treating pain
HK1079693A1 (en) Compositions for treating and/or preventing pollenosis
GB0303600D0 (en) Novel therapeutic method and compositions
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity
AU2002342188A8 (en) Methods and compositions for treating flavivirus-mediated disease
AU2003245524A8 (en) Cryosurgery compositions and methods

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application